Blue Faery's Benefactors Council Members
Our national membership giving program consists of corporations (and individuals) committed to giving a minimum annual gift of $5,000 per year for HCC-specific research, HCC educational programs, patient advocacy events, and/or corporate sponsorships.
View our 7th annual HCC Advocacy Partners Workshop (page is password-protected)
Blue Faery Benefactor
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Blue Faery Patron,
Founding Member
Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development, and commercialization of new medicines for difficult-to-treat cancers.
Blue Faery Supporter,
Founding Member
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases).
Blue Faery Supporter,
Founding Member
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious and life-threatening medical conditions.
Blue Faery Friend
Coherus Oncology is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer. For additional information, please visit coherus.com.
Blue Faery Friend
Eureka Therapeutics is a clinical-stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system.
Blue Faery Friend
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). We are dedicated to improving the quality of life by substantially alleviating the severe and debilitating effects of rare diseases with high unmet need. For more information, visit www.rezolutebio.com.